Repare Therapeutics Azioni (NASDAQ: RPTX)

Ultime notizie per Repare Therapeutics (NASDAQ:RPTX) Azioni

REPARE THERAPEUTICS INC

Repare Therapeutics

Repare Therapeutics Inc is a precision medicine oncology company focused on the development of synthetic lethality-based therapies for patients with cancer. The Company's focus is the research, development and commercialization of precision oncology drugs targeting specific vulnerabilities of tumors in genetically defined patient populations.

Cathie Wood Defies CoreWeave IPO Slump, Ark Snaps Up $3.6 Million Worth Of Stock In Nvidia-Backed Company

Equities

News

Markets

ETFs

ARKK

GTLB

HOOD

PATH

RPTX

Investimenti mirati: la società di investimento continua a puntare sulla piattaforma finanziaria nonostante le incertezze del mercato.

Cathie Wood raddoppia acquistando milioni di azioni nonostante i dazi di Trump

Trump’s Economic Gambit Sparks Fierce Debate As Cathie Wood Sees A Reagan-Style Boom, Obama Adviser Calls Musk’s Role A ‘Performance Art’

ARKG

ARKW

DKNG

EXAS

L&#39;investimento massiccio punta su due società innovative nel settore sanitario e dello sviluppo software. Cosa bolle in pentola?

Ark Invest di Cathie Wood scommette sull&#39;IA: ecco chi ha comprato

Repare Therapeutics Inc

<p>Teladoc Health (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TDOC#NYSE">TDOC</a>) has been analyzed by 11 analysts in the last three months, revealing a diverse range of perspectives from bullish to bearish.</p>
<p>The following table encapsulates their recent ratings, offering a glimpse into the evolving sentiments over the past 30 days and comparing them to the preceding months.</p>
<table>
<thead>
<tr>
<th></th>
<th align="right"><strong>Bullish</strong></th>
<th align="right"><strong>Somewhat Bullish</strong></th>
<th align="right"><strong>Indifferent</strong></th>
<th align="right"><strong>Somewhat Bearish</strong></th>
<th align="right"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td align="right">3</td>
<td align="right">1</td>
<td align="right">7</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
<p>Analysts have recently evaluated Teladoc Health and provided 12-month price targets. The average target is $9.43, accompanied by a high estimate of $13.00 and a low estimate of $7.00. This current average has decreased by 16.03% from the previous average price target of $11.23. </p>
<p><img src="https://www.benzinga.com/files/images/story/2025/1748368868_0.png" alt="price target chart" /></p>
<h2>Investigating Analyst Ratings: An Elaborate Study</h2>
<p>The analysis of recent analyst actions sheds light on the perception of Teladoc Health by financial experts. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Jailendra Singh</td>
<td>Truist Securities</td>
<td>Lowers</td>
<td>Hold</td>
<td>$9.00</td>
<td>$10.00</td>
</tr>
<tr>
<td>Stan Berenshteyn</td>
<td>Wells Fargo</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$8.00</td>
<td>$10.00</td>
</tr>
<tr>
<td>Richard Close</td>
<td>Canaccord Genuity</td>
<td>Lowers</td>
<td>Buy</td>
<td>$12.00</td>
<td>$14.00</td>
</tr>
<tr>
<td>David Roman</td>
<td>Goldman Sachs</td>
<td>Lowers</td>
<td>Buy</td>
<td>$10.00</td>
<td>$13.00</td>
</tr>
<tr>
<td>David Grossman</td>
<td>Stifel</td>
<td>Lowers</td>
<td>Hold</td>
<td>$8.00</td>
<td>$9.00</td>
</tr>
<tr>
<td>Elizabeth Anderson</td>
<td>Evercore ISI Group</td>
<td>Lowers</td>
<td>In-Line</td>
<td>$7.00</td>
<td>$8.00</td>
</tr>
<tr>
<td>Daniel Grosslight</td>
<td>Citigroup</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$8.75</td>
<td>$11.00</td>
</tr>
<tr>
<td>Glen Santangelo</td>
<td>Jefferies</td>
<td>Lowers</td>
<td>Hold</td>
<td>$8.00</td>
<td>$10.00</td>
</tr>
<tr>
<td>Allen Lutz</td>
<td>B of A Securities</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$8.00</td>
<td>$9.50</td>
</tr>
<tr>
<td>David Roman</td>
<td>Goldman Sachs</td>
<td>Lowers</td>
<td>Buy</td>
<td>$13.00</td>
<td>$16.00</td>
</tr>
<tr>
<td>Jessica Tassan</td>
<td>Piper Sandler</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$12.00</td>
<td>$13.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to Teladoc Health. This insight gives a snapshot of analysts' perspectives on the current state of the company.</li>
<li><strong>Rating:</strong> Offering insights into predictions, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Teladoc Health compared to the broader market.</li>
<li><strong>Price Targets:</strong> Analysts provide insights into price targets, offering estimates for the future value of Teladoc Health's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
<p>Capture valuable insights into Teladoc Health's market standing by understanding these analyst evaluations alongside pertinent financial indicators. Stay informed and make strategic decisions with our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/TDOC/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage"><strong>Stay up to date on Teladoc Health analyst ratings.</strong></a></p>
<p>If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">you can start by tracking it here</a>.</p>
<h2>Get to Know Teladoc Health Better</h2>
<p>Teladoc Health Inc is engaged in virtual care, forging a new healthcare experience with Better convenience, outcomes, and value. Its mission is to empower all people everywhere to live their healthiest lives by transforming the healthcare experience. It operates in Teladoc two segments Health Integrated Care and BetterHelp segments. The majority of its revenue is generated from access fees on a subscription basis (per member, per month). The balance comes from visit fees and equipment rental and sales to hospital systems.</p>
<h3>Teladoc Health's Economic Impact: An Analysis</h3>
<p><strong>Market Capitalization:</strong> Indicating a reduced size compared to industry averages, the company's market capitalization poses unique challenges.</p>
<p><strong>Decline in Revenue:</strong> Over the 3M period, Teladoc Health faced challenges, resulting in a decline of approximately <strong>-2.59%</strong> in revenue growth as of 31 March, 2025. This signifies a reduction in the company's top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Health Care sector.</p>
<p><strong>Net Margin:</strong> Teladoc Health's net margin is impressive, surpassing industry averages. With a net margin of <strong>-14.78%,</strong> the company demonstrates strong profitability and effective cost management.</p>
<p><strong>Return on Equity (ROE):</strong> Teladoc Health's ROE excels beyond industry benchmarks, reaching <strong>-6.37%</strong>. This signifies robust financial management and efficient use of shareholder equity capital.</p>
<p><strong>Return on Assets (ROA):</strong> Teladoc Health's ROA is below industry averages, indicating potential challenges in efficiently utilizing assets. With an ROA of <strong>-2.67%,</strong> the company may face hurdles in achieving optimal financial returns.</p>
<p><strong>Debt Management:</strong> With a below-average debt-to-equity ratio of <strong>1.11</strong>, Teladoc Health adopts a prudent financial strategy, indicating a balanced approach to debt management.</p>
<h2>The Core of Analyst Ratings: What Every Investor Should Know</h2>
<p>Analysts are specialists within banking and financial systems that typically report for specific stocks or within defined sectors. These people research company financial statements, sit in conference calls and meetings, and speak with relevant insiders to determine what are known as analyst ratings for stocks. Typically, analysts will rate each stock once a quarter. </p>
<p>Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.</p>
<p>If you want to keep track of which analysts are outperforming others, you can view updated analyst ratings along withanalyst success scores in <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>.</p>
<p><strong>Which Stocks Are Analysts Recommending Now?</strong></p>
<p>Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage"><strong>Click here to stay ahead of the market</strong></a>.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


Analyst Ratings

TDOC

Deep Dive Into Teladoc Health Stock: Analyst Perspectives (11 Ratings)

<p>Annaly Capital Management (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NLY#NYSE">NLY</a>) underwent analysis by 6 analysts in the last quarter, revealing a spectrum of viewpoints from bullish to bearish.</p>
<p>The following table provides a quick overview of their recent ratings, highlighting the changing sentiments over the past 30 days and comparing them to the preceding months.</p>
<table>
<thead>
<tr>
<th></th>
<th align="right"><strong>Bullish</strong></th>
<th align="right"><strong>Somewhat Bullish</strong></th>
<th align="right"><strong>Indifferent</strong></th>
<th align="right"><strong>Somewhat Bearish</strong></th>
<th align="right"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td align="right">1</td>
<td align="right">5</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td align="right">1</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
<p>Insights from analysts' 12-month price targets are revealed, presenting an average target of $20.44, a high estimate of $21.00, and a low estimate of $19.00. A 3.17% drop is evident in the current average compared to the previous average price target of $21.11. </p>
<p><img src="https://www.benzinga.com/files/images/story/2025/1748368860_0.png" alt="price target chart" /></p>
<h2>Interpreting Analyst Ratings: A Closer Look</h2>
<p>A clear picture of Annaly Capital Management's perception among financial experts is painted with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Kenneth Lee</td>
<td>RBC Capital</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$21.00</td>
<td>$22.00</td>
</tr>
<tr>
<td>Bose George</td>
<td>Keefe, Bruyette &amp; Woods</td>
<td>Raises</td>
<td>Outperform</td>
<td>$20.50</td>
<td>$20.15</td>
</tr>
<tr>
<td>Crispin Love</td>
<td>Piper Sandler</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$21.00</td>
<td>$21.50</td>
</tr>
<tr>
<td>Jason Weaver</td>
<td>Jones Trading</td>
<td>Maintains</td>
<td>Buy</td>
<td>$21.00</td>
<td>$21.00</td>
</tr>
<tr>
<td>Richard Shane</td>
<td>JP Morgan</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$19.00</td>
<td>$21.00</td>
</tr>
<tr>
<td>Bose George</td>
<td>Keefe, Bruyette &amp; Woods</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$20.15</td>
<td>$21.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to Annaly Capital Management. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li><strong>Rating:</strong> Offering a comprehensive view, analysts assess stocks qualitatively, spanning from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Annaly Capital Management compared to the broader market.</li>
<li><strong>Price Targets:</strong> Analysts explore the dynamics of price targets, providing estimates for the future value of Annaly Capital Management's stock. This examination reveals shifts in analysts' expectations over time.</li>
</ul>
<p>Navigating through these analyst evaluations alongside other financial indicators can contribute to a holistic understanding of Annaly Capital Management's market standing. Stay informed and make data-driven decisions with our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/NLY/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage"><strong>Stay up to date on Annaly Capital Management analyst ratings.</strong></a></p>
<h2>Delving into Annaly Capital Management's Background</h2>
<p>Annaly Capital Management Inc is an American mortgage real estate investment trust. Its business objective is to generate net income for distribution to its stockholders and optimize its returns through prudent management of its diversified investment strategies. The company's reportable operating segments are; the Agency segment, which invests in Agency mortgage-backed securities collateralized by residential mortgages; the Residential Credit segment, which invests in non-Agency residential whole loans and securitized products within the residential and commercial markets; the Mortgage Servicing Rights segment; and Corporate &amp; Other. Maximum revenue for the company is generated from its Agency segment.</p>
<h3>Financial Milestones: Annaly Capital Management's Journey</h3>
<p><strong>Market Capitalization Highlights:</strong> Above the industry average, the company's market capitalization signifies a significant scale, indicating strong confidence and market prominence.</p>
<p><strong>Decline in Revenue:</strong> Over the 3M period, Annaly Capital Management faced challenges, resulting in a decline of approximately <strong>-62.61%</strong> in revenue growth as of 31 March, 2025. This signifies a reduction in the company's top-line earnings. When compared to others in the Financials sector, the company faces challenges, achieving a growth rate lower than the average among peers.</p>
<p><strong>Net Margin:</strong> Annaly Capital Management's net margin is impressive, surpassing industry averages. With a net margin of <strong>48.58%,</strong> the company demonstrates strong profitability and effective cost management.</p>
<p><strong>Return on Equity (ROE):</strong> Annaly Capital Management's ROE is below industry averages, indicating potential challenges in efficiently utilizing equity capital. With an ROE of <strong>0.77%,</strong> the company may face hurdles in achieving optimal financial returns.</p>
<p><strong>Return on Assets (ROA):</strong> Annaly Capital Management's ROA lags behind industry averages, suggesting challenges in maximizing returns from its assets. With an ROA of <strong>0.08%,</strong> the company may face hurdles in achieving optimal financial performance.</p>
<p><strong>Debt Management:</strong> Annaly Capital Management's debt-to-equity ratio is below the industry average. With a ratio of <b>2.13</b>, the company relies less on debt financing, maintaining a healthier balance between debt and equity, which can be viewed positively by investors.</p>
<h2>How Are Analyst Ratings Determined?</h2>
<p>Experts in banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their comprehensive research involves attending company conference calls and meetings, analyzing financial statements, and engaging with insiders to generate what are known as analyst ratings for stocks. Typically, analysts assess and rate each stock once per quarter.</p>
<p>Analysts may supplement their ratings with predictions for metrics like growth estimates, earnings, and revenue, offering investors a more comprehensive outlook. However, investors should be mindful that analysts, like any human, can have subjective perspectives influencing their forecasts.</p>
<p><strong>Which Stocks Are Analysts Recommending Now?</strong></p>
<p>Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage"><strong>Click here to stay ahead of the market</strong></a>.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


Demystifying Annaly Capital Management: Insights From 6 Analyst Reviews

<p>Analysts' ratings for SoundHound AI (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SOUN#NASDAQ">SOUN</a>) over the last quarter vary from bullish to bearish, as provided by 6 analysts.</p>
<p>The table below offers a condensed view of their recent ratings, showcasing the changing sentiments over the past 30 days and comparing them to the preceding months.</p>
<table>
<thead>
<tr>
<th></th>
<th align="right"><strong>Bullish</strong></th>
<th align="right"><strong>Somewhat Bullish</strong></th>
<th align="right"><strong>Indifferent</strong></th>
<th align="right"><strong>Somewhat Bearish</strong></th>
<th align="right"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td align="right">4</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
<p>Providing deeper insights, analysts have established 12-month price targets, indicating an average target of $15.67, along with a high estimate of $26.00 and a low estimate of $10.00. A decline of 18.81% from the prior average price target is evident in the current average. </p>
<p><img src="https://www.benzinga.com/files/images/story/2025/1748368852_0.png" alt="price target chart" /></p>
<h2>Interpreting Analyst Ratings: A Closer Look</h2>
<p>The analysis of recent analyst actions sheds light on the perception of SoundHound AI by financial experts. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>James Fish</td>
<td>Piper Sandler</td>
<td>Announces</td>
<td>Overweight</td>
<td>$12.00</td>
<td>-</td>
</tr>
<tr>
<td>Scott Buck</td>
<td>HC Wainwright &amp; Co.</td>
<td>Lowers</td>
<td>Buy</td>
<td>$18.00</td>
<td>$26.00</td>
</tr>
<tr>
<td>Daniel Ives</td>
<td>Wedbush</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$15.00</td>
<td>$22.00</td>
</tr>
<tr>
<td>Gil Luria</td>
<td>DA Davidson</td>
<td>Lowers</td>
<td>Buy</td>
<td>$10.00</td>
<td>$13.00</td>
</tr>
<tr>
<td>Scott Buck</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$26.00</td>
<td>$26.00</td>
</tr>
<tr>
<td>Gil Luria</td>
<td>DA Davidson</td>
<td>Raises</td>
<td>Buy</td>
<td>$13.00</td>
<td>$9.50</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to SoundHound AI. This information offers a snapshot of how analysts perceive the current state of the company.</li>
<li><strong>Rating:</strong> Delving into assessments, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings communicate expectations for the relative performance of SoundHound AI compared to the broader market.</li>
<li><strong>Price Targets:</strong> Analysts explore the dynamics of price targets, providing estimates for the future value of SoundHound AI's stock. This examination reveals shifts in analysts' expectations over time.</li>
</ul>
<p>Capture valuable insights into SoundHound AI's market standing by understanding these analyst evaluations alongside pertinent financial indicators. Stay informed and make strategic decisions with our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/SOUN/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage"><strong>Stay up to date on SoundHound AI analyst ratings.</strong></a></p>
<h2>About SoundHound AI</h2>
<p>SoundHound AI Inc is an innovator of conversational intelligence, offering an independent Voice AI platform that enables businesses across industries to deliver high-quality conversational experiences to customers. The company's voice AI delivers speed and accuracy in numerous languages to product creators and service providers across retail, financial services, healthcare, automotive, smart devices, and restaurants via groundbreaking AI-driven products like Smart Answering, Smart Ordering, Dynamic Drive-Thru, and Amelia AI Agents.</p>
<h3>Breaking Down SoundHound AI's Financial Performance</h3>
<p><strong>Market Capitalization Perspectives:</strong> The company's market capitalization falls below industry averages, signaling a relatively smaller size compared to peers. This positioning may be influenced by factors such as perceived growth potential or operational scale.</p>
<p><strong>Revenue Growth:</strong> SoundHound AI displayed positive results in 3M. As of 31 March, 2025, the company achieved a solid revenue growth rate of approximately <strong>151.24%</strong>. This indicates a notable increase in the company's top-line earnings. When compared to others in the Information Technology sector, the company excelled with a growth rate higher than the average among peers.</p>
<p><strong>Net Margin:</strong> SoundHound AI's financial strength is reflected in its exceptional net margin, which exceeds industry averages. With a remarkable net margin of <strong>443.64%,</strong> the company showcases strong profitability and effective cost management.</p>
<p><strong>Return on Equity (ROE):</strong> SoundHound AI's ROE stands out, surpassing industry averages. With an impressive ROE of <strong>44.59%</strong>, the company demonstrates effective use of equity capital and strong financial performance.</p>
<p><strong>Return on Assets (ROA):</strong> SoundHound AI's ROA excels beyond industry benchmarks, reaching <strong>22.64%</strong>. This signifies efficient management of assets and strong financial health.</p>
<p><strong>Debt Management:</strong> SoundHound AI's debt-to-equity ratio is below industry norms, indicating a sound financial structure with a ratio of <strong>0.01</strong>.</p>
<h2>The Core of Analyst Ratings: What Every Investor Should Know</h2>
<p>Analysts work in banking and financial systems and typically specialize in reporting for stocks or defined sectors. Analysts may attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish "analyst ratings" for stocks. Analysts typically rate each stock once per quarter.</p>
<p>Analysts may enhance their evaluations by incorporating forecasts for metrics like growth estimates, earnings, and revenue, delivering additional guidance to investors. It is vital to acknowledge that, although experts in stocks and sectors, analysts are human and express their opinions when providing insights.</p>
<p><strong>Breaking: Wall Street's Next Big Mover</strong></p>
<p>Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantag"><strong>Click here for urgent details</strong></a>.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


SOUN

A Glimpse Into The Expert Outlook On SoundHound AI Through 6 Analysts

<p>Financial giants have made a conspicuous bullish move on ServiceNow. Our analysis of options history for ServiceNow (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NOW#NYSE">NOW</a>) revealed 42 unusual trades.</p>
<p>Delving into the details, we found 42% of traders were bullish, while 30% showed bearish tendencies. Out of all the trades we spotted, 12 were puts, with a value of $690,980, and 30 were calls, valued at $1,462,756.</p>
<h3>Expected Price Movements</h3>
<p>Based on the trading activity, it appears that the significant investors are aiming for a price territory stretching from $700.0 to $1200.0 for ServiceNow over the recent three months. </p>
<h3>Analyzing Volume &amp; Open Interest</h3>
<p>In today's trading context, the average open interest for options of ServiceNow stands at 171.96, with a total volume reaching 671.00. The accompanying chart delineates the progression of both call and put option volume and open interest for high-value trades in ServiceNow, situated within the strike price corridor from $700.0 to $1200.0, throughout the last 30 days.</p>
<h3>ServiceNow Call and Put Volume: 30-Day Overview</h3>
<p><img src="https://www.benzinga.com/files/images/story/2025/1748368841_0.png" alt="Options Call Chart" /></p>
<h3>Significant Options Trades Detected:</h3>
<p>
<table>
<thead>
<tr>
<th><strong>Symbol</strong></th>
<th><strong>PUT/CALL</strong></th>
<th><strong>Trade Type</strong></th>
<th><strong>Sentiment</strong></th>
<th><strong>Exp. Date</strong></th>
<th><strong>Ask</strong></th>
<th><strong>Bid</strong></th>
<th><strong>Price</strong></th>
<th><strong>Strike Price</strong></th>
<th><strong>Total Trade Price</strong></th>
<th align="right"><strong>Open Interest</strong></th>
<th align="right"><strong>Volume</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>NOW</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>01/16/26</td>
<td>$96.0</td>
<td>$95.9</td>
<td>$96.12</td>
<td>$1000.00</td>
<td>$144.3K</td>
<td align="right">323</td>
<td align="right">32</td>
</tr>
<tr>
<td>NOW</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>01/16/26</td>
<td>$61.5</td>
<td>$60.3</td>
<td>$61.5</td>
<td>$1200.00</td>
<td>$135.3K</td>
<td align="right">542</td>
<td align="right">17</td>
</tr>
<tr>
<td>NOW</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>09/19/25</td>
<td>$105.0</td>
<td>$101.6</td>
<td>$102.0</td>
<td>$1000.00</td>
<td>$102.0K</td>
<td align="right">298</td>
<td align="right">25</td>
</tr>
<tr>
<td>NOW</td>
<td>CALL</td>
<td>SWEEP</td>
<td>NEUTRAL</td>
<td>06/18/26</td>
<td>$142.0</td>
<td>$140.1</td>
<td>$140.1</td>
<td>$1100.00</td>
<td>$98.4K</td>
<td align="right">68</td>
<td align="right">7</td>
</tr>
<tr>
<td>NOW</td>
<td>PUT</td>
<td>SWEEP</td>
<td>NEUTRAL</td>
<td>01/16/26</td>
<td>$99.2</td>
<td>$93.9</td>
<td>$96.36</td>
<td>$1000.00</td>
<td>$96.2K</td>
<td align="right">323</td>
<td align="right">12</td>
</tr>
</tbody>
</table>
</p>
<h3>About ServiceNow</h3>
<p>ServiceNow Inc provides software solutions to structure and automate various business processes via a SaaS delivery model. The company primarily focuses on the IT function for enterprise customers. ServiceNow began with IT service management, expanded within the IT function, and more recently directed its workflow automation logic to functional areas beyond IT, notably customer service, HR service delivery, and security operations. ServiceNow also offers an application development platform as a service.</p>
<p>After a thorough review of the options trading surrounding ServiceNow, we move to examine the company in more detail. This includes an assessment of its current market status and performance.</p>
<h3>Current Position of ServiceNow</h3>
<ul>
<li>Currently trading with a volume of 491,356, the NOW's price is up by 0.86%, now at $1013.0. </li>
<li>RSI readings suggest the stock is currently may be approaching overbought.</li>
<li>Anticipated earnings release is in 57 days.</li>
</ul>
<h3>What The Experts Say On ServiceNow</h3>
<p>5 market experts have recently issued ratings for this stock, with a consensus target price of $1122.0.</p>
<p><strong>Turn $1000 into $1270 in just 20 days?</strong></p>
<p>20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. <a href="https://www.benzinga.com/premium/ideas/options-moneyline-2/?t=Moop1arja3be22op14&amp;adType=benzinga-insights&amp;ad=options-activity&amp;campaign=wallstreetadvantage"><strong>Click here for access</strong></a>.<br />
&#x2A; Maintaining their stance, an analyst from Citigroup continues to hold a Buy rating for ServiceNow, targeting a price of $1160.<br />
&#x2A; Showing optimism, an analyst from Truist Securities upgrades its rating to Buy with a revised price target of $1200.<br />
&#x2A; An analyst from RBC Capital persists with their Outperform rating on ServiceNow, maintaining a target price of $1100.<br />
&#x2A; Consistent in their evaluation, an analyst from Oppenheimer keeps a Outperform rating on ServiceNow with a target price of $1100.<br />
&#x2A; Maintaining their stance, an analyst from Stifel continues to hold a Buy rating for ServiceNow, targeting a price of $1050. </p>
<p>Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options traders manage this risk by educating themselves daily, scaling in and out of trades, following more than one indicator, and following the markets closely.</p>
<p>If you want to stay updated on the latest options trades for ServiceNow, <a href="https://www.benzinga.com/pro/">Benzinga Pro</a> gives you real-time options trades alerts.</p>


Options

Smart Money Is Betting Big In NOW Options

<p>During the last three months, 10 analysts shared their evaluations of Vertiv Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VRT#NYSE">VRT</a>), revealing diverse outlooks from bullish to bearish.</p>
<p>The table below summarizes their recent ratings, showcasing the evolving sentiments within the past 30 days and comparing them to the preceding months.</p>
<table>
<thead>
<tr>
<th></th>
<th align="right"><strong>Bullish</strong></th>
<th align="right"><strong>Somewhat Bullish</strong></th>
<th align="right"><strong>Indifferent</strong></th>
<th align="right"><strong>Somewhat Bearish</strong></th>
<th align="right"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td align="right">2</td>
<td align="right">5</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td align="right">2</td>
<td align="right">2</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
<p>In the assessment of 12-month price targets, analysts unveil insights for Vertiv Holdings, presenting an average target of $110.7, a high estimate of $150.00, and a low estimate of $85.00. Highlighting a 9.59% decrease, the current average has fallen from the previous average price target of $122.44. </p>
<p><img src="https://www.benzinga.com/files/images/story/2025/1748368839_0.png" alt="price target chart" /></p>
<h2>Deciphering Analyst Ratings: An In-Depth Analysis</h2>
<p>A clear picture of Vertiv Holdings's perception among financial experts is painted with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Amit Daryanani</td>
<td>Evercore ISI Group</td>
<td>Raises</td>
<td>Outperform</td>
<td>$150.00</td>
<td>$100.00</td>
</tr>
<tr>
<td>Stephen Tusa</td>
<td>JP Morgan</td>
<td>Raises</td>
<td>Overweight</td>
<td>$127.00</td>
<td>$100.00</td>
</tr>
<tr>
<td>Chris Snyder</td>
<td>Morgan Stanley</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$125.00</td>
<td>$140.00</td>
</tr>
<tr>
<td>Andrew Kaplowitz</td>
<td>Citigroup</td>
<td>Lowers</td>
<td>Buy</td>
<td>$98.00</td>
<td>$153.00</td>
</tr>
<tr>
<td>Mark Delaney</td>
<td>Goldman Sachs</td>
<td>Lowers</td>
<td>Buy</td>
<td>$85.00</td>
<td>$135.00</td>
</tr>
<tr>
<td>Stephen Tusa</td>
<td>JP Morgan</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$100.00</td>
<td>$132.00</td>
</tr>
<tr>
<td>Julian Mitchell</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$90.00</td>
<td>$100.00</td>
</tr>
<tr>
<td>Julian Mitchell</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$100.00</td>
<td>$111.00</td>
</tr>
<tr>
<td>Deane Dray</td>
<td>RBC Capital</td>
<td>Announces</td>
<td>Outperform</td>
<td>$121.00</td>
<td>-</td>
</tr>
<tr>
<td>Julian Mitchell</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$111.00</td>
<td>$131.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to Vertiv Holdings. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li><strong>Rating:</strong> Providing a comprehensive analysis, analysts offer qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of Vertiv Holdings compared to the broader market.</li>
<li><strong>Price Targets:</strong> Delving into movements, analysts provide estimates for the future value of Vertiv Holdings's stock. This analysis reveals shifts in analysts' expectations over time.</li>
</ul>
<p>Navigating through these analyst evaluations alongside other financial indicators can contribute to a holistic understanding of Vertiv Holdings's market standing. Stay informed and make data-driven decisions with our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/VRT/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage"><strong>Stay up to date on Vertiv Holdings analyst ratings.</strong></a></p>
<h2>Discovering Vertiv Holdings: A Closer Look</h2>
<p>Vertiv has roots tracing back to 1946 when its founder, Ralph Liebert, developed an air-cooling system for mainframe data rooms. As computers started making their way into commercial applications in 1965, Liebert developed one of the first computer room air conditioning, or CRAC, units, enabling the precise control of temperature and humidity. The firm has slowly expanded its data center portfolio through internal product development and the acquisition of thermal and power management products like condensers, busways, and switches. Vertiv has global operations today; its products can be found in data centers in most regions throughout the world.</p>
<h3>Financial Milestones: Vertiv Holdings's Journey</h3>
<p><strong>Market Capitalization:</strong> Boasting an elevated market capitalization, the company surpasses industry averages. This signals substantial size and strong market recognition.</p>
<p><strong>Revenue Growth:</strong> Vertiv Holdings's remarkable performance in 3M is evident. As of 31 March, 2025, the company achieved an impressive revenue growth rate of <strong>24.21%</strong>. This signifies a substantial increase in the company's top-line earnings. In comparison to its industry peers, the company stands out with a growth rate higher than the average among peers in the Industrials sector.</p>
<p><strong>Net Margin:</strong> The company's net margin is a standout performer, exceeding industry averages. With an impressive net margin of <strong>8.08%,</strong> the company showcases strong profitability and effective cost control.</p>
<p><strong>Return on Equity (ROE):</strong> Vertiv Holdings's financial strength is reflected in its exceptional ROE, which exceeds industry averages. With a remarkable ROE of <strong>6.45%,</strong> the company showcases efficient use of equity capital and strong financial health.</p>
<p><strong>Return on Assets (ROA):</strong> Vertiv Holdings's ROA surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive <strong>1.77%</strong> ROA, the company effectively utilizes its assets for optimal returns.</p>
<p><strong>Debt Management:</strong> Vertiv Holdings's debt-to-equity ratio is notably higher than the industry average. With a ratio of <b>1.18</b>, the company relies more heavily on borrowed funds, indicating a higher level of financial risk.</p>
<h2>The Significance of Analyst Ratings Explained</h2>
<p>Within the domain of banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their work involves attending company conference calls and meetings, researching company financial statements, and communicating with insiders to publish "analyst ratings" for stocks. Analysts typically assess and rate each stock once per quarter.</p>
<p>Some analysts also offer predictions for helpful metrics such as earnings, revenue, and growth estimates to provide further guidance as to what to do with certain tickers. It is important to keep in mind that while stock and sector analysts are specialists, they are also human and can only forecast their beliefs to traders.</p>
<p><strong>Which Stocks Are Analysts Recommending Now?</strong></p>
<p>Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage"><strong>Click here to stay ahead of the market</strong></a>.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


Assessing Vertiv Holdings: Insights From 10 Financial Analysts

<p><strong>Reservoir Media</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RSVR#NASDAQ">RSVR</a>) is set to give its latest quarterly earnings report on Wednesday, 2025-05-28. Here's what investors need to know before the announcement.</p>
<p>Analysts estimate that Reservoir Media will report an <strong>earnings per share</strong> (EPS) of $0.16. </p>
<p>The market awaits Reservoir Media's announcement, with hopes high for news of surpassing estimates and providing upbeat guidance for the next quarter.</p>
<p>It's important for new investors to understand that guidance can be a significant driver of stock prices.</p>
<h3>Earnings History Snapshot</h3>
<p>In the previous earnings release, the company beat EPS by $0.05, leading to a 1.08% drop in the share price the following trading session.</p>
<p>Here's a look at Reservoir Media's past performance and the resulting price change:</p>
<p>
<table>
<thead>
<tr>
<th><strong>Quarter</strong></th>
<th><strong>Q3 2025</strong></th>
<th><strong>Q2 2025</strong></th>
<th><strong>Q1 2025</strong></th>
<th><strong>Q4 2024</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>EPS Estimate</strong></td>
<td>0.03</td>
<td>0.03</td>
<td>0.03</td>
<td>0.01</td>
</tr>
<tr>
<td><strong>EPS Actual</strong></td>
<td>0.08</td>
<td>0</td>
<td>-0.01</td>
<td>0.04</td>
</tr>
<tr>
<td><strong>Price Change %</strong></td>
<td>-1.0%</td>
<td>-4.0%</td>
<td>-5.0%</td>
<td>-3.0%</td>
</tr>
</tbody>
</table>
</p>
<p><img src="https://www.benzinga.com/files/images/story/2025/1748368837_0.png" alt="eps graph" /></p>
<h3>Stock Performance</h3>
<p>Shares of Reservoir Media were trading at $7.23 as of May 26. Over the last 52-week period, shares are down 0%. Given that these returns are generally negative, long-term shareholders are likely a little upset going into this earnings release. </p>
<p><a href="https://www.benzinga.com/quote/RSVR/earnings"><strong>To track all earnings releases for Reservoir Media visit their earnings calendar on our site.</strong></a></p>
<p><em>This article was generated by Benzinga's automated content engine and reviewed by an editor.</em></p>


Earnings

RSVR

Insights into Reservoir Media's Upcoming Earnings

<p>Deep-pocketed investors have adopted a bearish approach towards Rigetti Computing (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RGTI#NASDAQ">RGTI</a>), and it's something market players shouldn't ignore. Our tracking of public options records at Benzinga unveiled this significant move today. The identity of these investors remains unknown, but such a substantial move in RGTI usually suggests something big is about to happen.</p>
<p>We gleaned this information from our observations today when Benzinga's options scanner highlighted 26 extraordinary options activities for Rigetti Computing. This level of activity is out of the ordinary.</p>
<p>The general mood among these heavyweight investors is divided, with 38% leaning bullish and 57% bearish. Among these notable options, 3 are puts, totaling $102,200, and 23 are calls, amounting to $1,127,414.</p>
<h3>What's The Price Target?</h3>
<p>Based on the trading activity, it appears that the significant investors are aiming for a price territory stretching from $1.5 to $37.0 for Rigetti Computing over the recent three months. </p>
<h3>Volume &amp; Open Interest Trends</h3>
<p>Looking at the volume and open interest is a powerful move while trading options. This data can help you track the liquidity and interest for Rigetti Computing's options for a given strike price. Below, we can observe the evolution of the volume and open interest of calls and puts, respectively, for all of Rigetti Computing's whale trades within a strike price range from $1.5 to $37.0 in the last 30 days. </p>
<h3>Rigetti Computing Call and Put Volume: 30-Day Overview</h3>
<p><img src="https://www.benzinga.com/files/images/story/2025/1748368836_0.png" alt="Options Call Chart" /></p>
<h3>Biggest Options Spotted:</h3>
<p>
<table>
<thead>
<tr>
<th><strong>Symbol</strong></th>
<th><strong>PUT/CALL</strong></th>
<th><strong>Trade Type</strong></th>
<th><strong>Sentiment</strong></th>
<th><strong>Exp. Date</strong></th>
<th><strong>Ask</strong></th>
<th><strong>Bid</strong></th>
<th><strong>Price</strong></th>
<th><strong>Strike Price</strong></th>
<th><strong>Total Trade Price</strong></th>
<th><strong>Open Interest</strong></th>
<th><strong>Volume</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>RGTI</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>01/16/26</td>
<td>$5.15</td>
<td>$5.0</td>
<td>$5.1</td>
<td>$12.00</td>
<td>$153.0K</td>
<td>10.8K</td>
<td>473</td>
</tr>
<tr>
<td>RGTI</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>01/15/27</td>
<td>$6.3</td>
<td>$6.1</td>
<td>$6.3</td>
<td>$15.00</td>
<td>$126.0K</td>
<td>5.0K</td>
<td>410</td>
</tr>
<tr>
<td>RGTI</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>01/15/27</td>
<td>$11.7</td>
<td>$11.45</td>
<td>$11.52</td>
<td>$2.50</td>
<td>$78.3K</td>
<td>675</td>
<td>73</td>
</tr>
<tr>
<td>RGTI</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>06/20/25</td>
<td>$1.5</td>
<td>$1.47</td>
<td>$1.5</td>
<td>$14.50</td>
<td>$75.0K</td>
<td>3.0K</td>
<td>521</td>
</tr>
<tr>
<td>RGTI</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>05/30/25</td>
<td>$1.05</td>
<td>$1.04</td>
<td>$1.04</td>
<td>$15.00</td>
<td>$61.9K</td>
<td>18.5K</td>
<td>1.0K</td>
</tr>
</tbody>
</table>
</p>
<h3>About Rigetti Computing</h3>
<p>Rigetti Computing Inc is engaged in the business of full-stack quantum computing. The company offers full-stack quantum computing platform as a cloud service to a wide range of end-users, directly through its Rigetti QCS platform, and also through cloud service providers. Its proprietary quantum-classical infrastructure provides ultra-low latency integration with public and private clouds for high-performance practical quantum computing. The company has developed the industry's first multi-chip quantum processor for scalable quantum computing systems. Geographically, the company derives the majority of its revenue from the United States.</p>
<p>After a thorough review of the options trading surrounding Rigetti Computing, we move to examine the company in more detail. This includes an assessment of its current market status and performance.</p>
<h3>Where Is Rigetti Computing Standing Right Now?</h3>
<ul>
<li>Currently trading with a volume of 64,284,544, the RGTI's price is up by 6.63%, now at $14.95. </li>
<li>RSI readings suggest the stock is currently may be overbought.</li>
<li>Anticipated earnings release is in 72 days.</li>
</ul>
<h3>What Analysts Are Saying About Rigetti Computing</h3>
<p>A total of 2 professional analysts have given their take on this stock in the last 30 days, setting an average price target of $14.5.</p>
<p><strong>Unusual Options Activity Detected: Smart Money on the Move</strong></p>
<p>Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22bz20&amp;adType=benzinga-insights&amp;ad=options-activity&amp;campaign=wallstreetadvantage"><strong>Click here for access</strong></a>.<br />
&#x2A; In a cautious move, an analyst from Benchmark downgraded its rating to Buy, setting a price target of $14.<br />
&#x2A; An analyst from Needham persists with their Buy rating on Rigetti Computing, maintaining a target price of $15. </p>
<p>Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options traders manage this risk by educating themselves daily, scaling in and out of trades, following more than one indicator, and following the markets closely.</p>
<p>If you want to stay updated on the latest options trades for Rigetti Computing, <a href="https://www.benzinga.com/pro/">Benzinga Pro</a> gives you real-time options trades alerts.</p>


RGTI

Rigetti Computing Unusual Options Activity

<p>Whales with a lot of money to spend have taken a noticeably bullish stance on <strong>Abercrombie &amp; Fitch</strong>.</p>
<p>Looking at options history for Abercrombie &amp; Fitch (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ANF#NYSE">ANF</a>) we detected 23 trades.</p>
<p>If we consider the specifics of each trade, it is accurate to state that 56% of the investors opened trades with bullish expectations and 39% with bearish.</p>
<p>From the overall spotted trades, 7 are puts, for a total amount of $1,901,458 and 16, calls, for a total amount of $549,629.</p>
<h3>What's The Price Target?</h3>
<p>Taking into account the Volume and Open Interest on these contracts, it appears that whales have been targeting a price range from $55.0 to $120.0 for Abercrombie &amp; Fitch over the last 3 months. </p>
<h3>Volume &amp; Open Interest Development</h3>
<p>In today's trading context, the average open interest for options of Abercrombie &amp; Fitch stands at 284.27, with a total volume reaching 11,539.00. The accompanying chart delineates the progression of both call and put option volume and open interest for high-value trades in Abercrombie &amp; Fitch, situated within the strike price corridor from $55.0 to $120.0, throughout the last 30 days.</p>
<h3>Abercrombie &amp; Fitch Option Volume And Open Interest Over Last 30 Days</h3>
<p><img src="https://www.benzinga.com/files/images/story/2025/1748368831_0.png" alt="Options Call Chart" /></p>
<h3>Significant Options Trades Detected:</h3>
<p>
<table>
<thead>
<tr>
<th><strong>Symbol</strong></th>
<th><strong>PUT/CALL</strong></th>
<th><strong>Trade Type</strong></th>
<th><strong>Sentiment</strong></th>
<th><strong>Exp. Date</strong></th>
<th><strong>Ask</strong></th>
<th><strong>Bid</strong></th>
<th><strong>Price</strong></th>
<th><strong>Strike Price</strong></th>
<th><strong>Total Trade Price</strong></th>
<th align="right"><strong>Open Interest</strong></th>
<th><strong>Volume</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>ANF</td>
<td>PUT</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>01/16/26</td>
<td>$5.9</td>
<td>$5.5</td>
<td>$5.6</td>
<td>$55.00</td>
<td>$1.1M</td>
<td align="right">286</td>
<td>2.0K</td>
</tr>
<tr>
<td>ANF</td>
<td>PUT</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>01/16/26</td>
<td>$5.7</td>
<td>$5.4</td>
<td>$5.6</td>
<td>$55.00</td>
<td>$560.0K</td>
<td align="right">286</td>
<td>3.0K</td>
</tr>
<tr>
<td>ANF</td>
<td>PUT</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>05/30/25</td>
<td>$4.9</td>
<td>$4.7</td>
<td>$4.71</td>
<td>$75.00</td>
<td>$61.2K</td>
<td align="right">83</td>
<td>2.1K</td>
</tr>
<tr>
<td>ANF</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>05/30/25</td>
<td>$2.15</td>
<td>$2.1</td>
<td>$2.15</td>
<td>$68.00</td>
<td>$57.8K</td>
<td align="right">95</td>
<td>573</td>
</tr>
<tr>
<td>ANF</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>11/21/25</td>
<td>$13.2</td>
<td>$12.7</td>
<td>$13.1</td>
<td>$80.00</td>
<td>$52.4K</td>
<td align="right">439</td>
<td>49</td>
</tr>
</tbody>
</table>
</p>
<h3>About Abercrombie &amp; Fitch</h3>
<p>Abercrombie &amp; Fitch Co is a specialty retailer that sells casual clothing, personal-care products, and accessories for men, women, and children. It sells direct to consumers through its stores and websites, which include the Abercrombie &amp; Fitch, Abercrombie kids, and Hollister brands. Most stores are in the United States, but the company does have many stores in Canada, Europe, and Asia. All stores are leased. Abercrombie ships to well over 100 countries via its websites. The company sources its merchandise from dozens of vendors that are primarily located in Asia and Central America. Abercrombie has two distribution centers in Ohio to support its North American operations. It uses third-party distributors for sales in Europe and Asia.</p>
<p>Following our analysis of the options activities associated with Abercrombie &amp; Fitch, we pivot to a closer look at the company's own performance.</p>
<h3>Abercrombie &amp; Fitch's Current Market Status</h3>
<ul>
<li>With a volume of 2,108,115, the price of ANF is up 4.11% at $76.17. </li>
<li>RSI indicators hint that the underlying stock may be approaching overbought.</li>
<li>Next earnings are expected to be released in 1 days.</li>
</ul>
<h3>What The Experts Say On Abercrombie &amp; Fitch</h3>
<p>In the last month, 5 experts released ratings on this stock with an average target price of $115.0.</p>
<p><strong>Unusual Options Activity Detected: Smart Money on the Move</strong></p>
<p>Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22bz20&amp;adType=benzinga-insights&amp;ad=options-activity&amp;campaign=wallstreetadvantage"><strong>Click here for access</strong></a>.<br />
&#x2A; An analyst from Jefferies persists with their Buy rating on Abercrombie &amp; Fitch, maintaining a target price of $135.<br />
&#x2A; An analyst from JP Morgan has decided to maintain their Overweight rating on Abercrombie &amp; Fitch, which currently sits at a price target of $142.<br />
&#x2A; Consistent in their evaluation, an analyst from Morgan Stanley keeps a Equal-Weight rating on Abercrombie &amp; Fitch with a target price of $78.<br />
&#x2A; Consistent in their evaluation, an analyst from Raymond James keeps a Outperform rating on Abercrombie &amp; Fitch with a target price of $90.<br />
&#x2A; An analyst from UBS has decided to maintain their Buy rating on Abercrombie &amp; Fitch, which currently sits at a price target of $130. </p>
<p>Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options traders manage this risk by educating themselves daily, scaling in and out of trades, following more than one indicator, and following the markets closely.</p>
<p>If you want to stay updated on the latest options trades for Abercrombie &amp; Fitch, <a href="https://www.benzinga.com/pro/">Benzinga Pro</a> gives you real-time options trades alerts.</p>


Looking At Abercrombie & Fitch's Recent Unusual Options Activity

<p><strong>MetLife's</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MET#NYSE">MET</a>) short percent of float has risen 7.02% since its last report. The company recently reported that it has <strong>6.83 million shares sold short</strong>, which is 1.22% of all regular shares that are available for trading. Based on its trading volume, <strong>it would take traders 2.05 days to cover their short positions on average.</strong></p>
<h3>Why Short Interest Matters</h3>
<p>Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.</p>
<p>Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.</p>
<p><strong>See Also:</strong> <a href="https://www.benzinga.com/short-interest?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage"><strong>List of the most shorted stocks</strong></a></p>
<h3>MetLife Short Interest Graph (3 Months)</h3>
<p><img src="https://www.benzinga.com/files/images/story/2025/1748368830_0.png" alt="short_fig" /></p>
<p>As you can see from the chart above the percentage of shares that are sold short for MetLife has grown since its last report. This does not mean that the stock is going to fall in the near-term but traders should be aware that more shares are being shorted.</p>
<h3>Comparing MetLife's Short Interest Against Its Peers</h3>
<p>Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.</p>
<p>According to <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>, MetLife's peer group average for short interest as a percentage of float is 2.91%, which means the company has <strong>less</strong> short interest than most of its peers.</p>
<p>Did you know that increasing short interest can actually be <strong>bullish</strong> for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage"><strong>This post by Benzinga Money explains how you can profit from it.</strong></a></p>
<p><em>This article was generated by Benzinga's automated content engine and was reviewed by an editor.</em></p>


Short Sellers

Short Ideas

Trading Ideas

What Does the Market Think About MetLife?

<p>Analysts' ratings for Moodys (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MCO#NYSE">MCO</a>) over the last quarter vary from bullish to bearish, as provided by 8 analysts.</p>
<p>The following table summarizes their recent ratings, shedding light on the changing sentiments within the past 30 days and comparing them to the preceding months.</p>
<table>
<thead>
<tr>
<th></th>
<th align="right"><strong>Bullish</strong></th>
<th align="right"><strong>Somewhat Bullish</strong></th>
<th align="right"><strong>Indifferent</strong></th>
<th align="right"><strong>Somewhat Bearish</strong></th>
<th align="right"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td align="right">0</td>
<td align="right">5</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td align="right">0</td>
<td align="right">4</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
<p>Analysts' evaluations of 12-month price targets offer additional insights, showcasing an average target of $511.25, with a high estimate of $572.00 and a low estimate of $456.00. A negative shift in sentiment is evident as analysts have decreased the average price target by 8.19%. </p>
<p><img src="https://www.benzinga.com/files/images/story/2025/1748368826_0.png" alt="price target chart" /></p>
<h2>Understanding Analyst Ratings: A Comprehensive Breakdown</h2>
<p>In examining recent analyst actions, we gain insights into how financial experts perceive Moodys. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ashish Sabadra</td>
<td>RBC Capital</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$550.00</td>
<td>$550.00</td>
</tr>
<tr>
<td>Shlomo Rosenbaum</td>
<td>Stifel</td>
<td>Lowers</td>
<td>Hold</td>
<td>$468.00</td>
<td>$533.00</td>
</tr>
<tr>
<td>Jeffrey Silber</td>
<td>BMO Capital</td>
<td>Lowers</td>
<td>Market Perform</td>
<td>$456.00</td>
<td>$475.00</td>
</tr>
<tr>
<td>Jeffrey Meuler</td>
<td>Baird</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$525.00</td>
<td>$575.00</td>
</tr>
<tr>
<td>Jason Haas</td>
<td>Wells Fargo</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$572.00</td>
<td>$610.00</td>
</tr>
<tr>
<td>Andrew Steinerman</td>
<td>JP Morgan</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$495.00</td>
<td>$585.00</td>
</tr>
<tr>
<td>Manav Patnaik</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$520.00</td>
<td>$570.00</td>
</tr>
<tr>
<td>Sean Kennedy</td>
<td>Mizuho</td>
<td>Announces</td>
<td>Neutral</td>
<td>$504.00</td>
<td>-</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to Moodys. This insight gives a snapshot of analysts' perspectives on the current state of the company.</li>
<li><strong>Rating:</strong> Gaining insights, analysts provide qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of Moodys compared to the broader market.</li>
<li><strong>Price Targets:</strong> Analysts explore the dynamics of price targets, providing estimates for the future value of Moodys's stock. This examination reveals shifts in analysts' expectations over time.</li>
</ul>
<p>Capture valuable insights into Moodys's market standing by understanding these analyst evaluations alongside pertinent financial indicators. Stay informed and make strategic decisions with our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/MCO/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage"><strong>Stay up to date on Moodys analyst ratings.</strong></a></p>
<h2>Unveiling the Story Behind Moodys</h2>
<p>Moody's, along with S&amp;P Ratings, is a leading provider of credit ratings on fixed-income securities. The ratings segment, Moody's Investors Service, includes corporates, structured finance, financial institutions, and public finance ratings. MIS represents a majority of the firm's profit and about half of the firm's revenue. The other segment, Moody's Analytics, consists of decision solutions, research and insights, and data and information.</p>
<h3>A Deep Dive into Moodys's Financials</h3>
<p><strong>Market Capitalization Analysis:</strong> With a profound presence, the company's market capitalization is above industry averages. This reflects substantial size and strong market recognition.</p>
<p><strong>Revenue Growth:</strong> Moodys's remarkable performance in 3M is evident. As of 31 March, 2025, the company achieved an impressive revenue growth rate of <strong>7.73%</strong>. This signifies a substantial increase in the company's top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Financials sector.</p>
<p><strong>Net Margin:</strong> Moodys's financial strength is reflected in its exceptional net margin, which exceeds industry averages. With a remarkable net margin of <strong>32.48%,</strong> the company showcases strong profitability and effective cost management.</p>
<p><strong>Return on Equity (ROE):</strong> Moodys's ROE excels beyond industry benchmarks, reaching <strong>17.21%</strong>. This signifies robust financial management and efficient use of shareholder equity capital.</p>
<p><strong>Return on Assets (ROA):</strong> Moodys's ROA excels beyond industry benchmarks, reaching <strong>4.08%</strong>. This signifies efficient management of assets and strong financial health.</p>
<p><strong>Debt Management:</strong> Moodys's debt-to-equity ratio is notably higher than the industry average. With a ratio of <b>1.93</b>, the company relies more heavily on borrowed funds, indicating a higher level of financial risk.</p>
<h2>Analyst Ratings: Simplified</h2>
<p>Within the domain of banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their work involves attending company conference calls and meetings, researching company financial statements, and communicating with insiders to publish "analyst ratings" for stocks. Analysts typically assess and rate each stock once per quarter.</p>
<p>Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.</p>
<p>If you want to keep track of which analysts are outperforming others, you can view updated analyst ratings along withanalyst success scores in <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>.</p>
<p><strong>Which Stocks Are Analysts Recommending Now?</strong></p>
<p>Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage"><strong>Click here to stay ahead of the market</strong></a>.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


Forecasting The Future: 8 Analyst Projections For Moodys

<p><strong>DuPont de Nemours's</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DD#NYSE">DD</a>) short percent of float has fallen 9.6% since its last report. The company recently reported that it has <strong>4.19 million shares sold short</strong>, which is 1.13% of all regular shares that are available for trading. Based on its trading volume, <strong>it would take traders 1.27 days to cover their short positions on average.</strong></p>
<h3>Why Short Interest Matters</h3>
<p>Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.</p>
<p>Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.</p>
<p><strong>See Also:</strong> <a href="https://www.benzinga.com/short-interest?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage"><strong>List of the most shorted stocks</strong></a></p>
<h3>DuPont de Nemours Short Interest Graph (3 Months)</h3>
<p><img src="https://www.benzinga.com/files/images/story/2025/1748368825_0.png" alt="short_fig" /></p>
<p>As you can see from the chart above the percentage of shares that are sold short for DuPont de Nemours has declined since its last report. This does not mean that the stock is going to rise in the near-term but traders should be aware that less shares are being shorted.</p>
<h3>Comparing DuPont de Nemours's Short Interest Against Its Peers</h3>
<p>Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.</p>
<p>According to <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>, DuPont de Nemours's peer group average for short interest as a percentage of float is 4.47%, which means the company has <strong>less</strong> short interest than most of its peers.</p>
<p>Did you know that increasing short interest can actually be <strong>bullish</strong> for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage"><strong>This post by Benzinga Money explains how you can profit from it.</strong></a></p>
<p><em>This article was generated by Benzinga's automated content engine and was reviewed by an editor.</em></p>


Peering Into DuPont de Nemours's Recent Short Interest

<p><strong>Coca-Cola's</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KO#NYSE">KO</a>) short percent of float has risen 5.62% since its last report. The company recently reported that it has <strong>40.19 million shares sold short</strong>, which is 0.94% of all regular shares that are available for trading. Based on its trading volume, <strong>it would take traders 2.36 days to cover their short positions on average.</strong></p>
<h3>Why Short Interest Matters</h3>
<p>Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.</p>
<p>Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.</p>
<p><strong>See Also:</strong> <a href="https://www.benzinga.com/short-interest?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage"><strong>List of the most shorted stocks</strong></a></p>
<h3>Coca-Cola Short Interest Graph (3 Months)</h3>
<p><img src="https://www.benzinga.com/files/images/story/2025/1748368820_0.png" alt="short_fig" /></p>
<p>As you can see from the chart above the percentage of shares that are sold short for Coca-Cola has grown since its last report. This does not mean that the stock is going to fall in the near-term but traders should be aware that more shares are being shorted.</p>
<h3>Comparing Coca-Cola's Short Interest Against Its Peers</h3>
<p>Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.</p>
<p>According to <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>, Coca-Cola's peer group average for short interest as a percentage of float is 7.93%, which means the company has <strong>less</strong> short interest than most of its peers.</p>
<p>Did you know that increasing short interest can actually be <strong>bullish</strong> for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage"><strong>This post by Benzinga Money explains how you can profit from it.</strong></a></p>
<p><em>This article was generated by Benzinga's automated content engine and was reviewed by an editor.</em></p>


What Does the Market Think About Coca-Cola?

<p>In the current session, the stock is trading at $445.12, after a <strong>1.54%</strong> spike. Over the past month, <strong>Gartner Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IT#NYSE">IT</a>)</strong> stock increased by <strong>5.83%</strong>, and in the past year, by <strong>4.06%</strong>. With performance like this, long-term shareholders are optimistic but others are more likely to look into the price-to-earnings ratio to see if the stock might be overvalued.</p>
<p>
</p><p><img src="https://www.benzinga.com/files/images/story/2025/1748368816_0.png" alt="Past Year Chart" /></p>

<h3>A Look at Gartner P/E Relative to Its Competitors</h3>
<p>The P/E ratio is used by long-term shareholders to assess the company's market performance against aggregate market data, historical earnings, and the industry at large. A lower P/E could indicate that shareholders do not expect the stock to perform better in the future or it could mean that the company is undervalued. </p>
<p>Gartner has a lower P/E than the aggregate P/E of <strong>30.41</strong> of the IT Services industry. Ideally, one might believe that the stock might perform worse than its peers, but it's also probable that the stock is undervalued. </p>
<p>
</p><p><img src="https://www.benzinga.com/files/images/story/2025/1748368816_1.png" alt="Guage" /></p>

<p>In conclusion, the price-to-earnings ratio is a useful metric for analyzing a company's market performance, but it has its limitations. While a lower P/E can indicate that a company is undervalued, it can also suggest that shareholders do not expect future growth. Additionally, the P/E ratio should not be used in isolation, as other factors such as industry trends and business cycles can also impact a company's stock price. Therefore, investors should use the P/E ratio in conjunction with other financial metrics and qualitative analysis to make informed investment decisions. </p>


Intraday Update

P/E Ratio Insights for Gartner

<p>4 analysts have shared their evaluations of Surgery Partners (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SGRY#NASDAQ">SGRY</a>) during the recent three months, expressing a mix of bullish and bearish perspectives.</p>
<p>The table below offers a condensed view of their recent ratings, showcasing the changing sentiments over the past 30 days and comparing them to the preceding months.</p>
<table>
<thead>
<tr>
<th></th>
<th align="right"><strong>Bullish</strong></th>
<th align="right"><strong>Somewhat Bullish</strong></th>
<th align="right"><strong>Indifferent</strong></th>
<th align="right"><strong>Somewhat Bearish</strong></th>
<th align="right"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td align="right">1</td>
<td align="right">2</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
<p>Analysts have recently evaluated Surgery Partners and provided 12-month price targets. The average target is $31.75, accompanied by a high estimate of $35.00 and a low estimate of $24.00. This current average represents a 1.55% decrease from the previous average price target of $32.25. </p>
<p><img src="https://www.benzinga.com/files/images/story/2025/1748368813_0.png" alt="price target chart" /></p>
<h2>Diving into Analyst Ratings: An In-Depth Exploration</h2>
<p>The standing of Surgery Partners among financial experts is revealed through an in-depth exploration of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Andrew Mok</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$24.00</td>
<td>$25.00</td>
</tr>
<tr>
<td>Bill Sutherland</td>
<td>Benchmark</td>
<td>Maintains</td>
<td>Buy</td>
<td>$35.00</td>
<td>$35.00</td>
</tr>
<tr>
<td>Ben Hendrix</td>
<td>RBC Capital</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$35.00</td>
<td>$35.00</td>
</tr>
<tr>
<td>Tao Qiu</td>
<td>Macquarie</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$33.00</td>
<td>$34.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to Surgery Partners. This offers insight into analysts' perspectives on the current state of the company.</li>
<li><strong>Rating:</strong> Delving into assessments, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings communicate expectations for the relative performance of Surgery Partners compared to the broader market.</li>
<li><strong>Price Targets:</strong> Analysts set price targets as an estimate of a stock's future value. Comparing the current and prior price targets provides insight into how analysts' expectations have changed over time. This information can be valuable for investors seeking to understand consensus views on the stock's potential future performance.</li>
</ul>
<p>Understanding these analyst evaluations alongside key financial indicators can offer valuable insights into Surgery Partners's market standing. Stay informed and make well-considered decisions with our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/SGRY/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage"><strong>Stay up to date on Surgery Partners analyst ratings.</strong></a></p>
<h2>Delving into Surgery Partners's Background</h2>
<p>Surgery Partners Inc is a healthcare services company with an integrated outpatient delivery model focused on providing quality, cost-effective solutions for surgical and related ancillary care in support of both patients and physicians. It has one reportable segment: Surgical Facilities which includes the operation of ASCs, surgical hospitals, anesthesia services, and multi-specialty physician practices, which earns revenues from contracts with patients in which the performance obligations are to provide health care services.</p>
<h3>Surgery Partners: Financial Performance Dissected</h3>
<p><strong>Market Capitalization Analysis:</strong> Below industry benchmarks, the company's market capitalization reflects a smaller scale relative to peers. This could be attributed to factors such as growth expectations or operational capacity.</p>
<p><strong>Revenue Growth:</strong> Surgery Partners's revenue growth over a period of 3M has been noteworthy. As of 31 March, 2025, the company achieved a revenue growth rate of approximately <strong>8.17%</strong>. This indicates a substantial increase in the company's top-line earnings. As compared to its peers, the company achieved a growth rate higher than the average among peers in Health Care sector.</p>
<p><strong>Net Margin:</strong> The company's net margin is below industry benchmarks, signaling potential difficulties in achieving strong profitability. With a net margin of <strong>-4.86%,</strong> the company may need to address challenges in effective cost control.</p>
<p><strong>Return on Equity (ROE):</strong> Surgery Partners's ROE surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive <strong>-2.14%</strong> ROE, the company effectively utilizes shareholder equity capital.</p>
<p><strong>Return on Assets (ROA):</strong> Surgery Partners's financial strength is reflected in its exceptional ROA, which exceeds industry averages. With a remarkable ROA of <strong>-0.48%,</strong> the company showcases efficient use of assets and strong financial health.</p>
<p><strong>Debt Management:</strong> With a below-average debt-to-equity ratio of <strong>2.22</strong>, Surgery Partners adopts a prudent financial strategy, indicating a balanced approach to debt management.</p>
<h2>How Are Analyst Ratings Determined?</h2>
<p>Experts in banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their comprehensive research involves attending company conference calls and meetings, analyzing financial statements, and engaging with insiders to generate what are known as analyst ratings for stocks. Typically, analysts assess and rate each stock once per quarter.</p>
<p>Some analysts also offer predictions for helpful metrics such as earnings, revenue, and growth estimates to provide further guidance as to what to do with certain tickers. It is important to keep in mind that while stock and sector analysts are specialists, they are also human and can only forecast their beliefs to traders.</p>
<p><strong>Breaking: Wall Street's Next Big Mover</strong></p>
<p>Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantag"><strong>Click here for urgent details</strong></a>.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


SGRY

Assessing Surgery Partners: Insights From 4 Financial Analysts

<p><strong>Trump Media &amp; Technology Group</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DJT#NASDAQ">DJT</a>) plunged 10% after announcing a massive $2.5 billion private placement—money earmarked for one of the largest Bitcoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>) treasury buys by a public company.</p>
<p>While the company <a href="https://www.globenewswire.com/news-release/2025/05/27/3088703/0/en/Trump-Media-Announces-Approximately-2-5-Billion-Bitcoin-Treasury-Deal.html">framed</a> the move as a bold step toward "financial freedom," the market wasn't buying it and neither was economist <strong>Peter Schiff</strong>.</p>
<p><figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"><br />
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true"><p lang="en" dir="ltr"><a href="https://twitter.com/search?q=%24DJT&amp;src=ctag&amp;ref_src=twsrc%5Etfw">$DJT</a> is down 10% on news it will raise $2.5 billion to buy Bitcoin. Maybe the markets don&#39;t have the appetite for yet another Bitcoin treasury company. Also, how can Trump&#39;s company front-run the Strategic Bitcoin Reserve, using taxpayers&#39; dollars to pump up what he bought first?</p>
<p>&mdash; Peter Schiff (@PeterSchiff) <a href="https://twitter.com/PeterSchiff/status/1927396617616752909?ref_src=twsrc%5Etfw">May 27, 2025</a></p></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
<p></p></figure></p>
<p>Schiff wasted no time slamming the deal on X, warning that <strong>Donald Trump</strong>'s company may be "front-running the Strategic Bitcoin Reserve" using what he claims is taxpayer-fueled capital to inflate a market Trump may have already entered personally.</p>
<p><strong>Read Also: <a href="https://www.benzinga.com/markets/25/05/45611864/trump-media-group-reportedly-plans-to-raise-3-billion-to-buy-cryptocurrencies-borrowing-a-page-from-mstr-playbook-says-peter-schiff">Trump Media Group Reportedly Plans To Raise $3 Billion To Buy Cryptocurrencies: &#8216;Borrowing A Page&#8217; From MSTR Playbook, Says Peter Schiff</a></strong></p>
<h2 class="wp-block-heading">Big Bitcoin, Bigger Backlash</h2>
<p>The deal, expected to close around May 29 involves issuing $1.5 billion in DJT stock and $1.0 billion in zero-coupon convertible notes. Trump Media says the capital will give it over $3 billion in liquid assets and lay the foundation for crypto-based subscriptions, utility tokens, and what CEO <strong>Devin Nunes</strong> calls "America First" business expansion.</p>
<p>But investors appear skeptical. The stock is now down more than 50% over the past year and 30% year-to-date. The sharp single-day sell-off underscores concerns that the company is pivoting too far into Bitcoin hype while revenue remains elusive.</p>
<h2 class="wp-block-heading">Peter Schiff Sounds Off</h2>
<p>Schiff, a longtime crypto critic, questioned both the strategy and ethics behind the move. "Maybe the markets don&#8217;t have the appetite for yet another Bitcoin treasury company," he said, adding a sharp jab: "How can Trump&#8217;s company front-run the Strategic Bitcoin Reserve, using taxpayers&#8217; dollars to pump up what he bought first?"</p>
<p>Whether or not the front-running charge sticks, Schiff's comments have struck a nerve with traders already spooked by the risky pivot.</p>
<h2 class="wp-block-heading">DJT Stock: Technicals Still Tempting Bulls</h2>
<p><figure class="wp-block-image size-full"><a href="https://www.benzinga.com/pro/register?utm_adType=bzprocontent&amp;utm_campaign=14daytrial&amp;utm_ad=0527"><img loading="lazy" decoding="async" width="631" height="486" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/27131749/Screenshot-2025-05-27-at-10.47.32-PM.png" alt="" class="wp-image-928815" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/27131749/Screenshot-2025-05-27-at-10.47.32-PM.png 631w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/27131749/Screenshot-2025-05-27-at-10.47.32-PM-300x231.png 300w" sizes="(max-width: 631px) 100vw, 631px" /></a></figure></p>
<p><em><a href="https://www.benzinga.com/pro/register?utm_adType=bzprocontent&amp;utm_campaign=14daytrial&amp;utm_ad=0527" target="_blank" rel="noreferrer noopener">Chart created using Benzinga Pro</a></em></p>
<p>Despite the sell-off, DJT stock is showing some signs of underlying support. The stock is trading above a 50-day simple moving average of $22.45, offering short-term bullish signals. It still sits below the 200-day SMA, which remains a long-term bearish flag. The MACD (moving average convergence/divergence) indicator reads 0.47, and the RSI (relative strength index) at 46.16 is nearing overbought territory—but not quite there yet.</p>
<p>It's a mess of mixed signals. But one thing is clear: Trump Media just made its boldest bet yet. And for now, the market is calling its bluff.</p>
<p><strong>Read Next: </strong></p>
<ul class="wp-block-list">
<li><strong><a href="https://www.benzinga.com/news/ipos/25/05/45448399/trump-insiders-want-a-piece-of-crypto-spac-action-is-a-merger-coming">Trump Insiders Want A Piece Of Crypto, SPAC Action: Is A Merger Coming?</a></strong></li>
</ul>
<p><em>Photo: Shutterstock</em></p>


Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

Social Media

Movers

Tech

General

$BTC

DJT Tanks 10% On Bitcoin Bet – Peter Schiff Warns Of Trump 'Front-Running The Reserve'

WIIM

MRVL

Marvell shares are trading higher after JP Morgan maintained bullish coverage on the stock, saying the company is tracking to drive $4 billion in AI revenues this year.

TAOP

TAOP stock has given up its prior loss. Taoping shares were trading lower after the company announced a 1-for-30 reverse stock split.

<p>Shares of <strong>D-Wave Quantum Inc</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/QBTS#NYSE">QBTS</a>) are trading lower by 7.5% to $17.39 during Tuesday&#8217;s session as the stock pulls back from recent highs. Here&#8217;s what investors <a href="https://www.benzinga.com/trading-ideas/movers/25/05/45518005/d-wave-quantum-stock-is-surging-tuesday-heres-why">need to know</a>.</p>
<p><strong>What To Know:</strong> Last week, D-Wave announced the general availability of its most advanced <a href="https://www.benzinga.com/pressreleases/25/05/b45514131/d-wave-announces-general-availability-of-advantage2-quantum-computer-its-most-advanced-and-perform">quantum computer</a>, the Advantage2 system. The sixth-generation quantum processor is designed to address real-world applications in optimization, AI and materials simulation. </p>
<p>It's now accessible via D-Wave's Leap quantum cloud service, offering sub-second response times and enterprise-grade security through SOC 2 Type 2 compliance. Additionally, the system is available for on-premises installation by hyperscale customers.</p>
<p><strong>Read Also: <a href="https://www.benzinga.com/news/25/05/45620675/soundhound-ai-soun-stock-jumps-15-whats-going-on">SoundHound AI Stock Jumps 15%: What&#8217;s Going On?</a></strong></p>
<p>CEO <strong>Alan Baratz</strong> hailed the launch as a major step forward for the quantum computing sector, emphasizing the Advantage2's ability to solve complex problems beyond the capabilities of even top-tier classical supercomputers. </p>
<p>The new system features increased qubit connectivity, improved energy scale, and enhanced coherence, all while enabling scalable coherent quantum annealing and hybrid solver integration.</p>
<p><strong>Price Action:</strong> Despite Tuesday&#8217;s drop, D-Wave shares are still higher by over 15% over the past week and are trading 139% higher from just a month ago.</p>
<p><strong>Read Also: <a href="https://www.benzinga.com/trading-ideas/long-ideas/25/05/45616366/nvidias-q1-earnings-loom-while-amds-edge-ai-bet-could-change-the-narrative">Nvidia&#8217;s Q1 Earnings Loom, While AMD&#8217;s Edge AI Bet Could Change The Narrative</a></strong></p>
<h2 class="wp-block-heading">How To Buy QBTS Stock</h2>
<p>By now you're likely curious about how to participate in the market for D-Wave Quantum &#8211; be it to purchase shares, or even attempt to bet against the company.</p>
<p>Buying shares is typically done through a brokerage account. You can find a list of <a href="https://www.benzinga.com/money/best-stock-trading-platforms">possible trading platforms here.</a> Many will allow you to buy &#8220;fractional shares,&#8221; which allows you to own portions of stock without buying an entire share.</p>
<p>In the case of D-Wave Quantum, which is trading at $17.39 as of publishing time, $100 would buy you 5.75 shares of stock.</p>
<p>If you're looking to bet against a company, the process is more complex. You'll need access to an options trading platform, or a broker who will allow you to &#8220;go short&#8221; a share of stock by lending you the shares to sell. The process of shorting a <a href="https://www.benzinga.com/money/how-to-short-a-stock">stock can be found at this resource.</a>  Otherwise, if your broker allows you to trade options, you can either buy a put option, or sell a call option at a strike price above where shares are currently trading &#8211; either way it allows you to profit off of the share price decline.</p>
<p><em>Photo: Courtesy of D-Wave Quantum</em></p>


QBTS

D-Wave Quantum (QBTS) Stock Falls: What's Driving Recent Volatility After Advantage2 Launch?

<p>Trading in the <strong>AES Corp</strong>&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AES#NYSE">AES</a>) is quiet on Tuesday. This comes after last week's sell-off of more than 20%. But a reversal may have started on Friday. There is a good chance the selling ended.</p>
<p>The stock is oversold at support and it formed a bullish engulfing pattern on the chart. These dynamics may result in a rally. This is why we have made it our <strong>Stock of the Day.</strong></p>
<p>Oversold means there has been aggressive and emotional selling. The stock has been pushed below what would be its typical or usual trading range.</p>
<p>This will draw buyers into the market. Many trading strategies and styles are built on the concept of reversion to the mean. These buyers will be anticipating a reversal or move higher. Their buying may become a self-fulfilling prophecy and push up the price.</p>
<p>AES is also close to a support level.</p>
<p><figure class="wp-block-image size-large"><img loading="lazy" decoding="async" width="1024" height="574" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/27133735/one-4-1024x574.png" alt="" class="wp-image-928837" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/27133735/one-4-1024x574.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/27133735/one-4-300x168.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/27133735/one-4-768x430.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/27133735/one-4.png 1447w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure></p>
<p><strong>Read Also: <a href="https://www.benzinga.com/economics/macro-economic-events/25/05/45616116/trumps-tariffs-may-trigger-an-inflation-shock-but-not-a-lasting-one-goldman-sachs-says">Trump&#8217;s Tariffs May Trigger An Inflation Shock &#8211; But Not A Lasting One, Goldman Sachs Says</a></strong></p>
<p>If a stock is trending lower, there are more shares for sale than there are to be bought. At a support level, the dynamic changes. There is enough demand to absorb all of the supply and the price stops heading lower.</p>
<p>Sometimes, stocks reverse and rally after they reach a support level. As you can see on the chart, this is what happened the last two times AES dropped to around $9.70.</p>
<p>On Friday, a bullish engulfing pattern formed on the chart. This could signal a change of leadership from the bears to the bulls.</p>
<p>On Friday morning, it looked like the recent downtrend would continue. The stock opened at a lower price than it closed at on Thursday.</p>
<p>But by the close, the tide had turned. The buyers overpowered the sellers and pushed the price higher. The closing price on Friday was above the opening price on Thursday.</p>
<p>Most volume in a stock typically trades near the open or close. Trading through Thursday's opening and closing prices shows that the buyers were very aggressive. The trading range on Friday &#8220;engulfed&#8221; Thursday's range.</p>
<p>As AES is oversold at support and just had a reversal pattern form on the chart, this means there is a good chance the stock moves higher.</p>
<p><strong>Read Next:</strong> <br />    • <a href="https://www.benzinga.com/trading-ideas/long-ideas/25/05/45616366/nvidias-q1-earnings-loom-while-amds-edge-ai-bet-could-change-the-narrative#google_vignette">Nvidia&#8217;s Q1 Earnings Loom, While AMD&#8217;s Edge AI Bet Could Change The Narrative</a></p>
<p><em>Photo: Shutterstock</em></p>


Technicals

Stock Of The Day: Has The AES Rally Started?

<p><a href="https://www.bloomberg.com/news/articles/2025-05-27/texas-adopts-online-child-safety-bill-opposed-by-apple-s-ceo?embedded-checkout=true">https://www.bloomberg.com/news/articles/2025-05-27/texas-adopts-online-child-safety-bill-opposed-by-apple-s-ceo?embedded-checkout=true</a></p>


AAPL

'Texas Adopts Online Child-Safety Bill Opposed by Apple's CEO'- Bloomberg

Press Releases

Repare Therapeutics to Host Webcast to Report Data from the Lunresertib and Camonsertib Combination Phase 1 MYTHIC Clinical Trial

Repare Therapeutics Announces Positive Results of the Lunresertib and Camonsertib Combination from the MYTHIC Phase 1 Gynecologic Expansion Clinical Trial

Opinion

How Cutting-Edge Immunotherapies Are Redefining Cancer Treatment Options

Repare Therapeutics Announces Portfolio Re-Prioritization, Partnering Initiatives and Cost Reductions

Repare Therapeutics Provides Business and Clinical Update and Reports Fourth Quarter and Full Year 2024 Financial Results

Repare Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Repare Therapeutics Announces Leadership Transitions

Repare Therapeutics Announces Six Abstracts Accepted for Presentation at AACR Annual Meeting 2025

Repare Therapeutics Announces Out-Licensing of its Discovery Platforms to DCx Biotherapeutics

Newly Launched DCx Biotherapeutics In-Licenses Discovery Platforms and Retains Talent and Infrastructure From Repare Therapeutics to Accelerate Development of Multi-Modal Antibody Drug Conjugates

Comments

Repare Therapeutics

Notizie

Ultime notizie per Repare Therapeutics (NASDAQ:RPTX) Azioni

Le persone guardano anche

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO